| Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. MDR Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W ... N Engl J Med. 377 (7), 644-657, 2017 | 7664* | 2017 |
| Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. P Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM ... N Engl J Med 380 (24), 2295-2306, 2019 | 4963* | 2019 |
| Alogliptin after acute coronary syndrome in patients with type 2 diabetes WB White, CP Cannon, SR Heller, SE Nissen, RM Bergenstal, GL Bakris, ... New England journal of medicine 369 (14), 1327-1335, 2013 | 3092 | 2013 |
| Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes FDKDI George L Bakris, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M ... N Engl J Med 383 (23), 2219-2229, 2020 | 1521* | 2020 |
| Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial AF Hernandez, JB Green, S Janmohamed, RB D'Agostino, CB Granger, ... The Lancet 392 (10157), 1519-1529, 2018 | 1329 | 2018 |
| Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes VCVI CP Cannon, R Pratley, S Dagogo-Jack, J Mancuso, S Huyck, U Masiukiewicz ... N Engl J Med 383 (15), 1425-1435, 2020 | 1230* | 2020 |
| Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes H Haller, S Ito, JL Izzo Jr, A Januszewicz, S Katayama, J Menne, ... New England Journal of Medicine 364 (10), 907-917, 2011 | 1076 | 2011 |
| Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease SPG Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, Lewis JB ... N Engl J Med. 384 (2), 129-139, 2021 | 850* | 2021 |
| Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes FDKDI Pitt B, Filippatos G, Agarwal R, Anker SD, Bakris GL, Rossing P ... N Engl J Med 385 (24), 2252-2263, 2021 | 813* | 2021 |
| Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial N Sherry, W Hagopian, J Ludvigsson, SM Jain, J Wahlen, RJ Ferry, ... The Lancet 378 (9790), 487-497, 2011 | 540 | 2011 |
| Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. ZD Heerspink HJL, Parving HH, Andress DL, Bakris G, Correa-Rotter R, Hou FF ... Lancet 393 (10184), 1937-1947, 2019 | 489 | 2019 |
| Ticagrelor in Patients with Stable Coronary Disease and Diabetes LLA Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C ... N Engl J Med. 381 (14), 1309-1320, 2019 | 332* | 2019 |
| Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk P Investigators N Engl J Med, doi: 10.1056/NEJMoa2210645., 2022 | 318* | 2022 |
| Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients D Ziegler, L Movsesyan, B Mankovsky, I Gurieva, Z Abylaiuly, I Strokov Diabetes care 32 (8), 1479-1484, 2009 | 288 | 2009 |
| Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial W Hagopian, RJ Ferry Jr, N Sherry, D Carlin, E Bonvini, S Johnson, ... Diabetes 62 (11), 3901-3908, 2013 | 251 | 2013 |
| The Canagliflozin and Renal Endpoints in Diabetes With Established Nephropathy Clinical Evaluation (CREDENCE) Study Rationale, Design, and Baseline Characteristics Am J Nephrol 46 (6), 462-472, 2017 | 241* | 2017 |
| Cerebrovascular disorders in patients with diabetes mellitus BN Mankovsky, BE Metzger, ME Molitch, J Biller Journal of Diabetes and its Complications 10 (4), 228-242, 1996 | 222 | 1996 |
| Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo … DL Bhatt, PG Steg, SR Mehta, LA Leiter, T Simon, K Fox, C Held, ... The Lancet 394 (10204), 1169-1180, 2019 | 200 | 2019 |
| Dose‐dependent effects of the once‐daily GLP‐1 receptor agonist lixisenatide in patients with type 2 diabetes inadequately controlled with metformin: a randomized, double‐blind … RE Ratner, J Rosenstock, G Boka, DRI6012 Study Investigators Diabetic Medicine 27 (9), 1024-1032, 2010 | 198 | 2010 |
| Stroke in patients with diabetes mellitus BN Mankovsky, D Ziegler Diabetes/metabolism research and reviews 20 (4), 268-287, 2004 | 182 | 2004 |
George BakrisProfessor The University of Chicago MedicineVerified email at uchicago.edu
